Company profile
PDS Biotechnology Corp
NASDAQ:PDSBBiotechnology: Pharmaceutical Preparations
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02065973 | phase1 | completed | 2014-02-01 | 2015-12-30 | PDS Biotechnology Corp. | An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101 |
| NCT06790966 | phase3 | terminated | 2025-05-30 | 2026-08-25 | PDS Biotechnology Corp. | Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma |
FDA applications (0)
No records yet.